ReviewWorld journal of gastroenterology2014
Non-invasive diagnosis of hepatitis B virus-related cirrhosis.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- KASL clinical practice guidelines for management of chronic hepatitis B.Clinical and molecular hepatology · 2019Guideline
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatology international · 2016Guideline
- Predictive value of hematological parameters in cirrhotic patients with open umbilical hernia repair.Hernia : the journal of hernias and abdominal wall surgery · 2024Article
- The Applicability of ADA, AFU, and LAC in the Early Diagnosis and Disease Risk Assessment of Hepatitis B-Associated Liver Cirrhosis and Hepatocellular Carcinoma.Frontiers in medicine · 2021Article
- A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B.Clinical and translational gastroenterology · 2019Article
- Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis.Disease markers · 2019Review
- Noninvasive Biomarkers in Assessment of Liver Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B.Open access Macedonian journal of medical sciences · 2018Article
- [Clinical value of noninvasive method in diagnosing hepatic fibrosis about chronic HBV carriers].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Review
- Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression.Future science OA · 2018Review
- Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment.Experimental and therapeutic medicine · 2017Article
- Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B.Experimental and therapeutic medicine · 2017Article
- Feasibility of A-mode ultrasound attenuation as a monitoring method of local hyperthermia treatment.Medical & biological engineering & computing · 2016Article
- Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B.Experimental and therapeutic medicine · 2016Article
- Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.World journal of gastroenterology · 2015Article
- Diffusion-weighted MRI for the assessment of liver fibrosis: principles and applications.BioMed research international · 2015Review
- A proteomic approach of biomarker candidate discovery for alcoholic liver cirrhosis.Journal of circulating biomarkersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B (CHB) infection is a major public health problem associated with significant morbidity and mortality worldwide. Twenty-three percent of patients with CHB progress naturally to liver cirrhosis, which was earlier thought to be irreversible. However, it is now known that cirrhosis can in fact be reversed by treatment with oral anti-nucleotide drugs. Thus, early and accurate diagnosis of cirrhosis is important to allow an appropriate treatment strategy to be chosen and to predict the prognosis of patients with CHB. Liver biopsy is the reference standard for assessment of liver fibrosis. However, the method is invasive, and is associated with pain and complications that can be fatal. In addition, intra- and inter-observer variability compromises the accuracy of liver biopsy data. Only small tissue samples are obtained and fibrosis is heterogeneous in such samples. This confounds the two types of observer variability mentioned above. Such limitations have encouraged development of non-invasive methods for assessment of fibrosis. These include measurements of serum biomarkers of fibrosis; and assessment of liver stiffness via transient elastography, acoustic radiation force impulse imaging, real-time elastography, or magnetic resonance elastography. Although significant advances have been made, most work to date has addressed the diagnostic utility of these techniques in the context of cirrhosis caused by chronic hepatitis C infection. In the present review, we examine the advantages afforded by use of non-invasive methods to diagnose cirrhosis in patients with CHB infections and the utility of such methods in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.